Research Article
Efficacy and Prognostic Factors for Y-90 Radioembolization (Y-90) in Metastatic Neuroendocrine Tumors with Liver Metastases
Table 2
Biochemical and clinical toxicities after Y-90 radioembolization, evaluated at 3 months posttreatment.
| | Biochemical and clinical toxicities | Number of patients (%) |
| | ALT (U/L) | | Grade 1 | 2 (4%) | | Grade 2 | 0 | | Grade 3 | 1 (2%) | | Grade 4 | 0 |
| | AST (U/L) | | Grade 1 | 11 (22%) | | Grade 2 | 1 (2%) | | Grade 3 | 1 (2%) | | Grade 4 | 0 |
| | ALP (U/L) | | Grade 1 | 26 (53%) | | Grade 2 | 3 (6%) | | Grade 3 | 0 | | Grade 4 | 1 (2%) |
| | WBC | | Grade 1 toxicity | 4 (8%) | | Grade 2 toxicity | 1 (2%) | | Grade 3 | 0 | | Grade 4 | 0 |
| | Bilirubin (μmol/L) | | Grade 1 toxicity | 5 (10%) | | Grade 2 toxicity | 0 | | Grade 3 | 0 | | Grade 4 | 0 |
| | Clinical toxicities | | Fatigue, grade 1 | 2 (4%) | | Abdominal pain, grade 3 | 3 (6%) | | Gastric ulceration, grade 1 | 1 (2%) | | Odynophagia, grade 1 | 1 (2%) |
|
|
AST = aspartate aminotransferase; ALT = alanine aminotransferase; ALP = alkaline phosphatase.
|
